Unveiling the antibreast cancer mechanism of Euphorbia hirta ethanol extract: computational and experimental study

References

• Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 71(3): 209-249.
   PubMed Web of Science ®Google Scholar
• Giaquinto, A.N., Sung, H., Miller, K.D., Kramer, J.L., Newman, L.A., Minihan. A., Jemal, A., Siegel, R.L. (2022). Breast Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians. 72(6): 524-541.
   PubMed Web of Science ®Google Scholar
• Hashemi, S.R., Zulkifli, I., Davoodi, H., Zunita, Z., Ebrahimi, M. (2012). Growth performance, intestinal microflora, plasma fatty acid profile in broiler chickens fed herbal plant (Euphorbia hirta) and mix of acidifiers. Animal Feed Science and Technology. 178(3-4): 167-174.
   Web of Science ®Google Scholar
• White, A.J., Bradshaw, P.T., Hamra, G.B. (2018). Air Pollution and Breast Cancer: a Review. Current Epidemiology Reports. 5(2): 92-100.
   PubMedGoogle Scholar
• Paplomata, E., O’Regan, R. (2014). The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Therapeutic Advances in Medical Oncology. 6(4): 154-166.
   PubMed Web of Science ®Google Scholar
• Maennling, A.E., Tur, M.K., Niebert, M., Klockenbring, T., Zeppernick, F., Gattenlöhner, S., Meinhold-Heerlein, I., Hussain, A.F. (2019). Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers. 11(12): 1826.
   PubMed Web of Science ®Google Scholar
• Ellis, H., Ma, C.X. (2019). PI3K Inhibitors in Breast Cancer Therapy. Current Oncology Reports. 21(12): 110.8.
   PubMed Web of Science ®Google Scholar
• Junttila, T.T., Akita, R.W., Parsons, K., Fields, C., Lewis Phillips, G.D., Friedman, L.S., Sampath, D., Sliwkowski, M.X. (2009). Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell. 15(5): 429-440.
   PubMed Web of Science ®Google Scholar
• Smyth, L.M., Zhou, Q., Nguyen, B., Yu, C., Lepisto, E.M., Arnedos, M., Hasset, M.J., Lenoue-Newton, M.L., Blauvelt, N., Dogan, S., Micheel, C.M., Wathoo, C., Horlings, H., Hudecek, J., Gross, B.E., Kundra, R ., Sweeney, S.M., Gao, J., Schultz, N., Zarski, A., Gardos, S.M., Lee, J., Sheffler-Collins, S., Park, B.H., Sawyers, C.L., André, F., Levy, M., Meric-Bernstam, F., Bedard, P.L., Iasonos, A., Schrag, D., Hyman, D.M., AACR Project GENIE Consortium. (2020). Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discovery. 10(4): 526-535.
   PubMed Web of Science ®Google Scholar
• Presti, D., Quaquarini, E. (2019). The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2-Metastatic Breast Cancer: Biological Mechanisms and New Treatments. Cancers. 11(9): 1242.
   PubMed Web of Science ®Google Scholar
• Holst, F., Stahl, P.R., Ruiz, C., Hellwinkel, O., Jehan, Z., Wendland, M., Lebeau, A., Terracciano, L., Al-Kuraya, K., Jänicke, F., Sauter, G., Simon, R. (2007). Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics. 39(5): 655-660.
   PubMed Web of Science ®Google Scholar
• Al-Snafi. (2017). PDAE. Pharmacology and therapeutic potential of Euphorbia hirta (Syn: Euphorbia pilulifera)- A review. IOSR Journal of Pharmacy. 07(03): 07-20.
   Google Scholar
• Kumar, S., Malhotra, R., Kumar, D. (2010). Euphorbia hirta: Its chemistry, traditional and medicinal uses, and pharmacological activities. Pharmacognosy Review. 4(7): 58-61.
   PubMedGoogle Scholar
• Linfang, H., Shilin, C., Meihua, Y. (2012). Euphorbia hirta (Feiyangcao): A review on its ethnopharmacology, phytochemistry and pharmacology. Journal of Medicinal Plants Research. 6(39): 5176-5185.
   Google Scholar
• Tran, N., Nguyen, M., Le, K.P., Nguyen, N., Tran, Q., Le, L. (2020). Screening of Antibacterial Activity, Antioxidant Activity, and Anticancer Activity of Euphorbia hirta Linn. Extracts. Applied Sciences. 10(23): 8408.
   Google Scholar
• Sharma, N., Samarakoon, K., Gyawali. R., Park, Y-H., Lee, S-J., Oh, S., Lee, T-H., Jeong, D. (2014). Evaluation of the Antioxidant, Anti-Inflammatory, and Anticancer Activities of Euphorbia hirta Ethanolic Extract. Molecules. 19(9): 14567-14581.
   PubMed Web of Science ®Google Scholar
• Anitha, P., Geegi, P., Yogeswari, J., Anthoni, S. (2014). In Vitro Anticancer Activity of Ethanolic Extract of Euphorbia hirta (L.). Science, Techno-logy and Arts Research Journal. 3(1): 8-13.
   Google Scholar
• Widyananda, M.H., Wicaksono, S.T., Rahmawati, K., Puspitarini, S., Ulfa, SM., Jatmiko, Y.D., Masruri, M., Widodo, N. (2022). A Potential Anticancer Mechanism of Finger Root (Boesenbergia rotunda) Extracts against a Breast Cancer Cell Line. Scientifica. 2022: 1-17.
   Web of Science ®Google Scholar
• O’Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics. 3(1): 33.
   PubMed Web of Science ®Google Scholar
• Trott, O., Olson, A.J. (2009). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry. 31(2): 455-461.
   Web of Science ®Google Scholar
• Krieger, E., Vriend, G. (2015). New ways to boost molecular dynamics simulations. Journal of Computational Chemistry. 36(13): 996-1007.
   PubMed Web of Science ®Google Scholar
• Fitriana, N., Rifa’i, M., Masruri, M., Wicaksono, S.T., Widodo, N. (2023). Anti-cancer effects of Curcuma zedoaria (Berg.) Roscoe ethanol extract on a human breast cancer cell line. Chemical Papers. 77(1): 399-411.
   Web of Science ®Google Scholar
• Whitty, A., Zhong, M., Viarengo, L., Beglov, D., Hall, D.R., Vajda, S. (2016). Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. Drug Discovery Today. 21(5): 712-717.
   PubMed Web of Science ®Google Scholar
• Liu, H., Wei, M., Yang, X., Yin, C., He, X. (2017). Development of TLSER model and QSAR model for predicting partition coefficients of hydrophobic organic chemicals between low density polyethylene film and water. Science of The Total Environment. 574: 1371-1378.
   PubMed Web of Science ®Google Scholar
• Yunta, M.R.J. (2017). It Is Important to Compute Intramolecular Hydrogen Bonding in Drug Design? American Journal of Modeling and Optimization. 5(1): 24-57.
   Google Scholar
• Lomize, A.L., Hage, J.M., Schnitzer, K., Golobokov, K., LaFaive, M.B., Forsyth, A.C., Pogozheva, I.D. (2019). PerMM: A Web Tool and Database for Analysis of Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. Journal of Chemical Information and Modeling. 59(7): 3094-3099.
   PubMed Web of Science ®Google Scholar
• Filimonov, D.A., Lagunin, A.A., Gloriozova, T.A., Rudik, A.V., Druzhilovskii, D.S., Pogodin, P.V., Poroikov, V.V. (2014). Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource. Chemistry of Heterocyclic Compounds. 50(3): 444-457.
   Web of Science ®Google Scholar
• Lagunin, A.A., Rudik, A.V., Pogodin, P.V., Savosina, P.I., Tarasova, O.A., Dmitriev, A.V., Ivanov, S.M., Biziukova, N.Y., Druzhilovskiy, D.S., Filimonov, D.A., Poroikov, V.V. (2023). CLC-Pred 2.0: A Freely Available Web Appli-cation for In Silico Prediction of Human Cell Line Cytotoxicity and Molecular Mechanisms of Action for Druglike Compounds. International Journal of Molecular Sciences. 24(2): 1689.
   PubMed Web of Science ®Google Scholar
• Banerjee, P., Eckert, A.O., Schrey, A.K., Preissner, R. (2018). ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Research. 46(W1): W257-W263.
   PubMed Web of Science ®Google Scholar
• Yang, D., Wang, T., Long, M., Li, P. (2020). Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine. Oxidative Medicine and Cellular Longevity. 2020: 1-13.
   Web of Science ®Google Scholar
• Rauf, A., Imran, M., Khan, I.A., ur-Rehman, M., Gilani, S.A., Mehmood, Z., Mubarak, M.S. (2018). Anticancer potential of quercetin: A comprehensive review. Phytotherapy Research. 32(11): 2109-2130
   PubMed Web of Science ®Google Scholar
• Taheri, Y., Sharifi-Rad, J., Antika, G., Yılmaz, Y.B., Tumer, T.B., Abuhamdah, S., Chandra, S., Saklani, S., Kılıç, C.S., Sestito, S., Daştan, S.D., Kumar, M., Alshehri, M.M., Rapposelli, S., Cruz-Martins, N., Cho, W. (2021). Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits. Oxidative Medicine and Cellular Longevity. 2021: 1-20.
   Web of Science ®Google Scholar
• Tuorkey, M.J. (2016). Molecular targets of luteolin in cancer. European Journal of Cancer Prevention. 25(1): 65-76.
   PubMed Web of Science ®Google Scholar
• Chakka, R., Dakshinamurthy, R.V., Rawal, P., Appajappa S.B., Pramanik, S. (2023). Gallic acid a flavonoid isolated from Euphorbia hirta antagonizes gamma radiation induced radiotoxicity in lymphocytes in vitro. Journal of Complementary and Integrative Medicine. 20(1): 146-152.
   PubMedGoogle Scholar
• Zhao, J., Khan, I.A., Fronczek, F.R. (2011). Gallic acid. Acta Crystallographica Section E. 67(2): o316-o317.
   PubMedGoogle Scholar
• Mardani-Ghahfarokhi, A., Farhoosh, R. (2020). Antioxidant activity and mechanism of inhibitory action of gentisic and α-resorcylic acids. Scientific Reports. 10(1): 19487.
   PubMed Web of Science ®Google Scholar
• Altinoz, M.A., Elmaci, .I, Cengiz, S., Emekli-Alturfan, E., Ozpinar, A. (2018). From epidemiology to treatment: Aspirin’s prevention of brain and breast-cancer and cardioprotection may associate with its metabolite gentisic acid. Chemico-Biological Interactions. 291: 29-39.
   PubMed Web of Science ®Google Scholar
• Singh, A., Chauhan, S., Tripathi, V. (2018). Quinic acid attenuates oral cancer cell proliferation by downregulating cyclin D1 Expression and Akt signaling. Pharmacognosy Magazine. 14(55): 14.
   Web of Science ®Google Scholar
• Perumal, S., Mahmud, R., Ismail, S. (2016). Mechanism of action of isolated caffeic acid and epicatechin 3-gallate from Euphorbia hirta against Pseudomonas aeruginosa. Pharma-cognosy Magazine. 13(50): 311.
   Web of Science ®Google Scholar
• Alam, M., Ashraf, G.M., Sheikh, K., Khan, A., Ali, S., Ansari, Md.M., Adnan, M., Pasupuleti, V.R., Hassan, Md.I. (2022). Potential Therapeutic Implications of Caffeic Acid in Cancer Signaling: Past, Present, and Future. Frontiers in Pharmacology. 13: 845871.
   PubMedGoogle Scholar
• Piñero, J., Ramírez-Anguita, J.M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., Furlong, L.I. (2019). The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Research. 48: D845-D855.
   Web of Science ®Google Scholar
• Daina, A., Michielin, O., Zoete, V. (2019). SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Research. 47(W1): W357-W364.
   PubMed Web of Science ®Google Scholar
• Wu, P., Heins, Z.J., Muller, J.T., Katsnelson, L., De Bruijn, I., Abeshouse, A.A., Schultz, N., Fenyö, D., Gao, J. (2019). Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal. Molecular & Cellular Proteomics. 18(9): 1893-1898.
   PubMed Web of Science ®Google Scholar
• Hu, X., Li, J., Fu, M., Zhao, X., Wang, W. (2021). The JAK/STAT signaling pathway: from bench to clinic. Signal Transduction and Targeted Therapy, 6(1): 402.
   PubMed Web of Science ®Google Scholar
• Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., Baradaran, B. (2019). The relation between PI3K/AKT signalling pathway and cancer. Gene. 698: 120-128.
   PubMed Web of Science ®Google Scholar
• Singh, I. (2013). Targeting EGFR and IGF 1R a promising combination therapy for metastatic cancer. Frontiers in Bioscience. S5(1): 231-246.
   Google Scholar
• Modi, S.J., Kulkarni, V.M. (2019). Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Pers-pective. Medicine in Drug Discovery. 2: 100009.
   Google Scholar
• Jackson, N.M., Ceresa, B.P. (2017). EGFR-mediated apoptosis via STAT3. Experimental Cell Research. 356(1): 93-103.
   PubMed Web of Science ®Google Scholar
• Luo, J., Zou, H., Guo, Y., Tong, T., Ye, L., Zhu, C., Deng, L., Wang, B., Pan, Y., Li, P. (2022). SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Research. 24(1): 99.
   PubMed Web of Science ®Google Scholar
• Menendez, J.A., Lupu, R. (2017). Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opinion on Therapeutic Targets. 21(11): 1001-1016.
   PubMed Web of Science ®Google Scholar
• Pernas, S., Tolaney, S.M., Winer, E.P., Goel, S. (2018). CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances in Medical Oncology. 10: 175883591878645.
   PubMed Web of Science ®Google Scholar
• Gaviraghi, M., Rabellino, A., Andolfo, A., Brand, M., Brombin, C., Bagnato, P., De Feudis, G., Raimondi, A., Locatelli, A., Tosoni, D., Mazza, D., Gianni, L., Tonon, G., Yarden, Y., Tacchetti, C., Daniele, T. (2020). Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation. Scientific Reports. 2020: 10(1): 16906.
   PubMed Web of Science ®Google Scholar
• Schroeder, R., Stevens, C., Sridhar, J. (2014). Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer. Molecules. 19(9): 15196-15212.
   PubMed Web of Science ®Google Scholar
• Rashidi, M., Seghatoleslam, A., Namavari, M., Amiri, A., Fahmidehkar, M.A., Ramezani, A., Eftekhar, E., Hosseini, A., Erfani, N., Fakher, S. (2017). Selective Cytotoxicity and Apoptosis-Induction of Cyrtopodion scabrum Extract Against Digestive Cancer Cell Lines. International Journal of Cancer Management. 10(5): e8633.
   Web of Science ®Google Scholar
• Zorova, L.D., Popkov, V.A., Plotnikov, E.Y., Silachev, D.N., Pevzner, I.B., Jankauskas, S.S., Babenko, V.A., Zorov, S.D., Balakireva, A.V., Juhaszova, M., Sollott, S.J., Zorov, D.B. (2018). Mitochondrial membrane potential. Analytical Biochemistry. 552: 50-59.
   PubMed Web of Science ®Google Scholar
• Sakamuru, S., Attene-Ramos, M.S., Xia, M. (2016). Mitochondrial Membrane Potential Assay. In: Zhu, H., Xia. M, ed. High-Throughput Screening Assays in Toxicology.Vol 1473. Methods in Molecular Biology. New York, NY: Springer New York. Pp. 17-22.
   Google Scholar
• Gentilini, D., Busacca, M., Di Francesco, S., Vignali, M., Viganò, P., Di Blasio, A.M. (2007). PI3K/Akt And ERK1/2 signalling pathways are involved in endometrial cell migration induced by 17β-estradiol and growth factors. MHR: Basic science of reproductive medicine. 13(5): 317-322.
   Google Scholar
• Adwan, H., Bäuerle, T.J., Berger, M.R. (2004). Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Therapy. 11(2): 109-120.
   PubMed Web of Science ®Google Scholar
• Muranen, T., Meric-Bernstam, F., Mills, G.B. (2014). Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors. Cancer Cell. 26(1): 7-9.
   PubMed Web of Science ®Google Scholar
• Yang, Y., Du, J., Hu, Z., Liu, J., Tian, Y., Zhu, Y., Wang, L., Gu, L. (2011). Activation of Rac1-PI3K/Akt is required for epidermal growth factor-induced PAK1 activation and cell migration in MDA-MB-231 breast cancer cells. Journal of Biomedical Research. 25(4): 237-245.
   PubMedGoogle Scholar
• Zhang, X., Ge, Y-L., Zhang, S-P., Yan, P., Tian, R-H. (2014). Downregulation of KDR expression induces apoptosis in breast cancer cells. Cellular and Molecular Biology Letters. 19(4): 527-541.
   PubMed Web of Science ®Google Scholar
• Wang, S., Konorev, E.A., Kotamraju, S., Joseph, J., Kalivendi, S., Kalyanaraman, B. (2004). Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms. Journal of Biological Chemistry. 279(24): 25535-25543.
   PubMed Web of Science ®Google Scholar
• Luque-Bolivar, A., Pérez-Mora, E., Villegas, V.E., Rondón-Lagos, M. (2020). Resistance and Overcoming Resistance in Breast Cancer. Breast Cancer: Targets and Therapy. 12: 211-229.
   PubMed Web of Science ®Google Scholar
• Rather, M.A., Bhat, B.A., Qurishi, M.A. (2013). Multicomponent phytotherapeutic approach gaining momentum: Is the “one drug to fit all” model breaking down? Phytomedicine. 21(1): 1-14.
   PubMed Web of Science ®Google Scholar